April 9th 2021

OrganOx appoints Juliet Thompson as Non-Executive Director to the Board

OrganOx is delighted to announce the appointment of Juliet Thompson as Non-Executive Director to the Board, Chair of the Audit Committee and member of the Remuneration Committee at OrganOx.

“I am delighted to be joining OrganOx, a leading liver transplant company focussing on improving outcomes for transplant recipients” said Juliet.

According to Chairman of the Board, Dr Oern Stuge,  “Juliet is very informed and insightful and therefore there is no surprise that she is already adding tremendous value inside and outside the Board room. I speak on behalf of the whole Board when I say we very much look forward to working with Juliet as we take the Company to the next level.”

Juliet brings a wealth of relevant experience.  Over the past 20 years Juliet has been actively involved in the life sciences sector working as an investment banker and strategic adviser to healthcare companies in Europe.

Juliet headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code. Juliet sits on the boards of public companies Vectura plc and Novacyt S.A. and chairs the Audit Committee of both companies.